Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
Christopher A. Eide, Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L. Savage, Serena Muratcioğlu, Noah Merz, Richard D. Press, Thomas O’Hare, Thomas Jacob, Tania Q. Vu, Cristina E. Tognon, Tara A. Macey, John Kuriyan, Charalampos G. Kalodimos, Brian Druker
Topics & Concepts
PonatinibMyeloid leukemiaDrug resistanceCancer researchMutantMutationAcquired resistanceAllosteric regulationMedicinePharmacologyBiologyDasatinibImatinibGeneticsInternal medicineReceptorGeneChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia research